Posted on December 11, 2017
In September 2017, HPV World, the only scientific newsletter on HPV research in the world, published its third edition, focusing on questions related to single-dose efficacy of the HPV vaccines. Aimée R. Kreimer, Ph.D., senior investigator in the Infections and Immunoepidemiology Branch, served as the scientific guest editor. She is featured in a front-page interview, and co-authored an article on single-dose efficacy with senior investigator Joshua Sampson, Ph.D., of the Biostatistics Branch, and others.
Kreimer invited commentaries from experts across the HPV research continuum. John T. Schiller, Ph.D., senior investigator in the NCI Center for Cancer Research, and co-inventor of the technology behind the HPV vaccines, writes about the biological rationale for a one-dose vaccine. Mark Schiffman, M.D., M.P.H., and Nicolas Wentzensen, M.D., Ph.D., both senior investigators in the Clinical Genetics Branch, present their arguments in favor of the HPV FASTER approach—a simplified screening strategy for controlling cervical cancer, particularly in low-resource settings.